Atara Biotherapeutics Inc(ATRA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.4 | Insider Own | 30.97% | Shs Outstand | 9.4M | Perf Week | -6.75% |
| Market Cap | 0.08B | Forward P/E | 8.51 | EPS next Y | 236.15% | Insider Trans | 10.11% | Shs Float | 6.9M | Perf Month | -5.32% |
| Enterprise Value | 0.12B | PEG | - | EPS next Q | -0.13 | Inst Own | 48.12% | Short Float | 5.05% | Perf Quarter | -6.32% |
| Income | -0.02B | P/S | 12.99 | EPS this Y | -126.9% | Inst Trans | -2.19% | Short Ratio | 8.24 | Perf Half Y | 63.47% |
| Sales | 0.01B | P/B | - | EPS next 5Y | - | ROA | -57.62% | Short Interest | 0.35M | Perf YTD | -55.72% |
| Book/sh | -3.92 | P/C | 8.15 | EPS past 3/5Y | - | ROE | - | 52W High | -58.16% ($19.15) | Perf Year | -42.97% |
| Cash/sh | 0.98 | P/FCF | - | Sales past 3/5Y | 23.85% - | ROIC | -135.76% | 52W Low | 104.34% ($3.92) | Perf 3Y | -75.16% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -253.97% | Gross Margin | 91.38% | Volatility(W/M) | 6.88% 7.14% | Perf 5Y | -97.93% |
| Dividend TTM | - | EV/Sales | 19.7 | Sales Y/Y TTM | -96.72% | Oper. Margin | -238.73% | ATR (14) | 0.62 | Perf 10Y | -97.64% |
| Dividend Ex-Date | - | Quick Ratio | 1.98 | EPS Q/Q | -265.86% | Profit Margin | -269.42% | RSI (14) | 37.55 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.98 | Sales Q/Q | -96.42% | SMA20 | -11.81% ($9.08) | Beta | 0.29 | Target Price | $13.67 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/12 | SMA50 | -12.9% ($9.2) | Rel Volume | 0.7 | Prev Close | $8.53 |
| Employees | 14 | LT Debt/Eq | - | EPS/Sales Surpr. | -1.59% 14.55% | SMA200 | 4.31% ($7.68) | Avg Volume(3M) | 0.04M | Price | $8.01 |
| IPO | 2014/10/16 | Option/Short | No/Yes | Trades | 445 | Volume | 29,937 | Change | -6.1% |
🧬 Atara Biotherapeutics (ATRA) is a US biotech company developing allogeneic (donor-derived) T-cell-based cell therapies. Through its off-the-shelf treatment candidates using donor-derived immune cells, the company targets post-transplant viral-associated diseases and immune disorders. It is classified as a clinical-stage, research and development-focused company.
Over the past 1 year, roughly in the middle
58% below its 1-year high.
Traded less than usual. That is 70% of its average volume.
ATRA has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -126.9% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,299. Peers typically go for $1,010.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 48.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #376 of 595 in the industry
Based on market cap of $80M.
RANI#374 Rani Therapeutics Holdings Inc $82M PER - 
CRBP#375 Corbus Pharmaceuticals Holdings Inc $82M PER - ATRA#376 Atara Biotherapeutics Inc $80M PER - 
CNXU#377 Conexeu Sciences Inc $78M PER - 
CLLS#378 Cellectis ADR $78M PER - 
FAQ
What kind of company is ATRA?
ATRA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ATRA?
The market cap of ATRA is approximately $80M, ranking 4,584 within its sector.
What is the 52-week high and low for ATRA?
ATRA has recorded a 52-week high of $19.15 and a low of $3.92.
